摘要
目的:探讨不同剂量吡柔比星膀胱灌注预防非肌层浸润性膀胱癌的有效性和安全性。方法:将216例非肌层浸润性膀胱癌患者随机分成三组,行经尿道膀胱肿瘤电切术(TURBt术)后分别应用吡柔比星30 mg(90例)、40mg(64例)、50mg(62例)加入0.9%氯化钠溶液30ml中膀胱灌注化疗,比较各组患者2年内膀胱肿瘤复发情况及灌注后不良反应发生情况。结果:50mg组(14.5%)的2年复发率较30mg组(41.1%)和40mg组(32.8%)明显降低(P<0.05),且50mg组平均复发时间为(14.30±3.10)个月,较30mg组(8.30±2.80)个月和40mg组(7.50±2.60)个月明显延长(P<0.01);各组均有发生膀胱刺激征患者,50mg组发生率(40.3%)明显高于30mg组(21.1%)和40mg组(18.8%)(P<0.01),但经对症处理后症状均可缓解。结论:非肌层浸润性膀胱癌患者行TURBt术后使用吡柔比星50mg膀胱灌注治疗更能有效抑制膀胱肿瘤复发,且不良反应可控。
Objective：To evaluate the effectiveness and safety of different doses of pirarubicin on preventing non-muscle invasive bladder cancer recurrence by intravesical instillation.Method：Two hundred and sixteen patients with non-muscle invasive bladder cancer were randomly divided into three groups.They were treated with different doses of pirarubicin by intravesical instillation after TURBt：30mg（n=90）,40mg（n=64）and 50mg（n=62）dissolved in 30 ml of physiological saline.Then two-year recurrence rate and the adverse reaction after bladder perfusion therapy were compared.Result：The two-year recurrence rate in 50 mg group（14.5%）was lower than those in 30 mg group（41.1%）and 40 mg group（32.8%）（P〈0.05）,and the mean recurrence time of 50 mg group（14.30±3.10）months was longer than those of 30 mg group（8.30±2.80）months and 40 mg group（7.50±2.60）months（P〈0.01）.The irritative symptoms were found in every group,but a higher rate in50 mg group（40.3%）than those in 30 mg group（21.1%）and 40 mg group（18.8%）（P〈0.01）was found.All of these adverse reactions were alleviated after heteropathy.Conclusion：We recommend using pirarubicin at the dose of 50 mg for preventing non-muscle invasive bladder cancer recurrence by intravesical instillation.
作者
邓新军
李正明
李颂
李刚
黄文胜
施国强
DENG Xinjun LI Zhengming LI Song LI Gang HUANG Wensheng SHI Guoqiang(Department of Urology, Guangzhou Red Cross Hospital, Medical College of Jinan University, Guangzhou, 510220, China)
出处
《临床泌尿外科杂志》
2017年第3期226-228,共3页
Journal of Clinical Urology
关键词
非肌层浸润性膀胱癌
吡柔比星
复发
膀胱灌注
non-muscle invasive bladder cancer
pirarubicin
recurrence
intravesical instillation
